ENABLING REMOTE scRNAseq PHARMA STUDIES

COLLECT SAMPLES ACROSS THE GLOBE WITH CENTRALIZED PROCESSING

Key Takeaways

  • Cryopreservation damages fragile and sparse cells, biasing samples
  • Samples collected and shipped in the HIVE™ scRNAseq device are preserved and retain the complexity of the sample.
  • The HIVE™ scRNAseq device enables pharma studies that rely on remotely collected samples by facilitating their storage and shipping.
Enabling Remote scRNAseq Pharma Studies

Check out our application note:
Enabling Remote scRNAseq Pharma Studies

Request more information about the HIVE™ scRNAseq Solution

Biopharma looks to single-cell RNAseq1 for biomarker discovery, to identify targets that can personalize therapy and increase efficacy. Most scRNAseq technologies require complex equipment that is too expensive for sample collection sites, forcing biopharma to rely on cryopreservation to ship samples to advanced research labs across the globe. Cryopreservation damages fragile and sparse cells, biasing samples—what you freeze is not what you thaw.

The HIVE™ scRNAseq Solution enables scRNAseq studies with global sample collection and centralized lab processing. Technicians at collection sites can gently and reproducibly capture single cells from fragile or sparse samples. As you ship your samples worldwide, the HIVE™ scRNAseq Solution locks the single-cell molecular signature as if it was fresh, giving researchers access to single-cell resolution for samples collected across the globe.

BREAKING DRUG DISCOVERY BARRIERS FOR BIOPHARMA

Cryopreservation Compromises Results

  • Freezing damages fragile cells:
    • Sample bias (neutrophil dropout)
  • Irreproducible for sparse samples
    • FNAs with 50–100K cells/mL

Pilot Study Proves the HIVE™ scRNAseq Solution Concept

  • Research: Hepatitis B virus
  • Sample type: Minimally invasive biopsies
  • Global access: Sample collection in Europe
  • scRNAseq: Shipping to central lab in US

Future Studies will Tackle Challenging Studies

  • Global trials ongoing for 6–24 months
  • Longitudinal tracking for each individual
The HIVE™ scRNAseq device enables pharma studies that rely on remotely collected samples by facilitating their storage and shipping while retaining the complexity of the sample.

ROBUST & SPECIFIC EXPRESSION ACROSS CELL TYPES

The HIVE™ scRNAseq device enables robust and specific expression across various cell types.

THREE EUROPEAN DONORS, TWO PAIRED SAMPLES, PROCESSING IN THE US

Collection at Site in Europe

  • 3 healthy human donors:
    • Paired filtered blood and liver FNAs
  • Single cells loaded and frozen on-site

Transport from Europe-to-US

  • 2–3 weeks in transit

Central Lab Processing

  • scRNAseq processing in US

Reproducible performance with minimal intersample variability

The HIVE™ scRNAseq device enables reproducible performance with minimal intersample variability between samples before and after shipping internationally.

SINGLE-CELL INSIGHTS USING THE HIVE™ scRNAseq SOLUTION

More Accurate Sample Representation

  • HIVE™ scRNAseq Solution recovered:
    • Neutrophils that are normally lost by cryopreservation
    • Transcriptional heterogeneity amongst neutrophils

Tissue-specific Insights

  • Observed tissue-resident populations:
    • NK cells in FNAs but absent in peripheral blood
The HIVE™ scRNAseq device delivers more accurate sample representation than samples preserved using cryopreservation.

Reference

  1. Genshaft, A., Subudhi, S., Keo, A. et al. Clinical implementation of single-cell RNA sequencing using liver fine needle aspirate tissue sampling and centralized processing captures compartment specific immuno-diversity. bioRxiv 11.30.470634 (2021). https://doi.org/10.1101/2021.11.30.470634
Request more information about the HIVE™ scRNAseq Solution

For research use only. Not for use in diagnostic procedures.